医学
内科学
心脏病学
心房颤动
预测值
全身炎症
糖尿病
炎症
价值(数学)
试验预测值
胰岛素
作者
Bi-Yu Gao,Ming‐Cheng Lin
标识
DOI:10.1093/qjmed/hcaf307
摘要
Zeng et al. reported that glycaemic variability (GV) and the systemic immune-inflammation index (SII) were independently and jointly associated with atrial fibrillation (AF) in type 2 diabetes mellitus.1 Several underexplored patterns and methodological weaknesses, however, merit further consideration. The AF prevalence exceeded 60% in both cohorts,1 indicating a highly enriched inpatient population and introducing spectrum bias. Such enrichment can exaggerate odds ratios and discrimination metrics, thereby limiting generalisability to outpatient contexts where AF prevalence is considerably lower. GV was derived from non-standardised inpatient glucose measurements,1 which often reflect acute physiological stress, treatment adjustments, and variations in monitoring frequency rather than enduring metabolic instability. Previous research demonstrated that long-term visit-to-visit GV, rather than short-term inpatient fluctuations, predicted incident AF in diabetes,2 underscoring the importance of distinguishing acute from chronic variability. Pronounced imbalances in coronary disease and renal dysfunction were also evident between AF and non-AF groups.1 Large cohort analyses have shown that systemic inflammatory biomarkers frequently reflect underlying cardiovascular burden,3 and SII has been associated with broader cardiometabolic clustering rather than isolated inflammatory activity.4 These findings suggest that GV and SII may partly represent comorbidity severity rather than independent AF determinants. Although the combined GV-SII model improved the area under the curve, its sensitivity was lower than that of SII alone—an important concern for AF detection strategies that prioritise avoiding missed cases. Because glycaemic variability is influenced by pharmacological, physiological, and contextual factors,5 validation using standardised glucose monitoring and more representative populations is essential before clinical implementation.
科研通智能强力驱动
Strongly Powered by AbleSci AI